Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MoonLake Immunotherapeutics (NASDAQ: MLTX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as it develops sonelokimab, an investigational Nanobody® targeting IL‑17A and IL‑17F, for inflammatory skin and joint diseases. As a Cayman Islands–incorporated issuer listed on Nasdaq, MoonLake files reports and current event disclosures with the Securities and Exchange Commission that document material agreements, clinical milestones and financial results.
Among the key documents are Form 8‑K filings, which MoonLake uses to report material events such as the pricing of an underwritten offering of Class A ordinary shares, entry into a term loan facility, and press releases announcing quarterly financial results. 8‑K filings also reference clinical and regulatory developments, including Phase 3 VELA trial data in hidradenitis suppurativa (HS), Phase 2 LEDA results in palmoplantar pustulosis (PPP), interim analyses from the VELA‑TEEN adolescent HS study, and updates on the broader sonelokimab trial portfolio.
Investors can use this page to review how MoonLake describes its financial condition, capital structure and key agreements in official SEC documents. Filings may incorporate press releases that summarize cash balances, research and development spending, non-dilutive financing arrangements, and expectations regarding the funding of Phase 2 and Phase 3 programs in HS, psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and PPP.
Stock Titan enhances these filings with AI-powered tools that help interpret lengthy disclosures. Users can quickly identify the purpose of a given 8‑K, locate references to clinical trial data, and understand the context of equity offerings or debt facilities. Real-time updates from EDGAR ensure that new MoonLake filings appear promptly, while structured access makes it easier to follow how regulatory, clinical and financing developments are reflected in the company’s official record.
MoonLake Immunotherapeutics’ major shareholder group affiliated with BVF Partners reported substantial open-market sales of Class A Ordinary Shares. On March 31, 2026, the reporting entities sold a combined 3,750,000 shares at $16.79 per share in multiple transactions.
The filing is made jointly by several funds and entities in a Section 13(d) group that collectively owns more than 10% of MoonLake’s common stock, each disclaiming beneficial ownership beyond its pecuniary interest. After these sales, individual reporting entities still report multi‑million share holdings.
The group also reports indirect holdings of three “Option to Buy” awards over 6,682, 7,688 and 11,297 Class A Ordinary Shares with exercise prices of $48.83, $42.44 and $29.18, expiring in 2035, 2034 and 2033 respectively. Two options are fully vested, while the 6,682‑share grant will vest in full by June 5, 2026 or at the next annual general meeting, subject to Spike Loy’s continued service.
MoonLake Immunotherapeutics’ major shareholder group BVF and affiliates report owning 16,001,284 Class A ordinary shares, or about 22.3% of the 71,727,875 shares outstanding as of February 1, 2026. The holdings are spread across several BVF funds and a managed account.
On March 31, 2026, BVF sold 1,932,354 shares at $16.79 per share, BVF II sold 1,569,116 shares at $16.79, and Biotechnology Value Trading Fund OS sold 248,530 shares at $16.79. Despite these sales, the BVF complex remains a large beneficial owner with shared voting and dispositive power across its entities.
The filing discloses a proposed sale of 3,750,000 shares of Common Stock on NASDAQ. The record shows an aggregate offering price of $63,487,500.00 and a reported position of 71,727,875 shares with an as of date of 03/31/2026. The shares include 18,501,284 shares identified as merger consideration acquired on 04/05/2022.
MoonLake Immunotherapeutics is a clinical-stage biotech focused on a single asset, sonelokimab (SLK), a tri-specific IL‑17A/IL‑17F Nanobody for inflammatory skin and joint diseases. The company is targeting hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), palmoplantar pustulosis (PPP) and related IL‑17‑driven conditions.
Phase 3 HS trials (VELA‑1 and VELA‑2) showed clinically meaningful HiSCR75 responses and consistent safety, supporting plans to submit a Biologics License Application for adult and adolescent HS in the second half of 2026, with a potential first U.S. launch in the second half of 2027, subject to approval. A Phase 3 adolescent HS study (VELA‑TEEN) reported strong interim responses.
In PsA, the Phase 2b ARGO trial delivered high ACR and PASI response rates versus placebo and an adalimumab reference arm, and two global Phase 3 trials (IZAR‑1 and IZAR‑2) are underway with key readouts expected in 2026. Phase 2 data in PPP (LEDA) and axSpA (S‑OLARIS) also showed substantial symptom improvements, and SLK obtained FDA Fast Track designation in moderate‑to‑severe PPP. MoonLake relies on third‑party manufacturing and an exclusive license from Merck Healthcare KGaA and expects to invest further in commercialization, manufacturing, and intellectual property as it advances SLK toward potential approval.
MoonLake Immunotherapeutics entered into an amended senior secured term loan facility totaling $500.0 million with Hercules Capital, drawing $25.0 million and leaving up to $400.0 million of additional non-dilutive funding available across future tranches tied to clinical, regulatory and market-cap milestones.
The amended agreement adds a conditional revenue covenant if the fifth tranche is used, but has no scheduled amortization and allows full prepayment with declining fees. MoonLake also reported positive Phase 2 S-OLARIS data in axial spondyloarthritis, with 81% of sonelokimab-treated patients achieving an ASAS40 response at week 12 and more than 80% showing clinically important ASDAS-CRP improvement, supported by MRI, PET and biomarker data, and a safety profile consistent with prior trials.
As of December 31, 2025, the company held $394.0 million in cash, cash equivalents and short-term marketable debt securities and expects this to fund operations and capital needs into the second half of 2027. Director Simon Sturge will resign effective February 28, 2026, with Jorge Santos da Silva becoming Interim Chair and Spike Loy appointed Lead Independent Director.
Cormorant Asset Management, LP and Bihua Chen have disclosed a significant ownership stake in MoonLake Immunotherapeutics. They report beneficial ownership of 4,355,433 Class A ordinary shares, representing 6.10% of the class. All voting and investment power over these shares is shared, with no sole voting or dispositive authority.
The filing states that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of MoonLake Immunotherapeutics. The report is made jointly by Cormorant Asset Management, LP and Bihua Chen under Schedule 13G rules.
MoonLake Immunotherapeutics reported that its Chief Financial Officer, Matthias Bodenstedt, received an award of 354,296 Class A ordinary shares on January 7, 2026. The shares were granted at a price of $0 per share as restricted stock, meaning they are subject to vesting conditions rather than being fully transferable immediately.
According to the filing, these restricted shares will vest in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, as long as he continues to serve the company through each vesting date. After this grant, Bodenstedt beneficially owned a total of 1,276,305 Class A ordinary shares, all held directly.
MoonLake Immunotherapeutics reported that Chief Executive Officer and director Jorge Santos da Silva received a new stock option award. On January 7, 2026, he was granted an option to buy 520,342 Class A ordinary shares at an exercise price of $11.29 per share. The option runs until January 7, 2036.
These options vest over time, rather than all at once. The award vests in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, and each vesting installment requires his continued service with the company through the relevant date. The filing shows he holds these derivative securities directly.
MoonLake Immunotherapeutics reported an equity award to a senior executive. Chief Scientific Officer Kristian Reich filed a Form 4 showing a grant of stock options covering 520,342 Class A ordinary shares at an exercise price of $11.29 per share.
The options were granted on January 7, 2026 and vest in four equal annual installments on January 7, 2027, 2028, 2029, and 2030, as long as he continues to serve the company through each vesting date. Following this grant, he holds 520,342 derivative securities directly.
MoonLake Immunotherapeutics reported that it received positive feedback from the U.S. Food and Drug Administration on the clinical evidence strategy for its drug candidate Sonelokimab (SLK) in hidradenitis suppurativa, following a requested Type B FDA meeting. This feedback relates to how the company is generating the clinical data needed to support SLK in this indication.
The company also plans to hold an Investor Day on February 23, 2026 at 8:00 a.m. Eastern Time to discuss the outcomes of the Type B FDA meeting in more detail and to present new clinical data for SLK across multiple indications. A press release with these updates was filed as an exhibit to this report.